New hope for painful skin condition: experimental drug LAD328 enters phase 2 trial
NCT ID NCT07547813
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether the experimental drug LAD328 can reduce symptoms of hidradenitis suppurativa, a chronic skin condition causing painful lumps. About 50 adults with moderate-to-severe disease will receive either LAD328 or a placebo. The main goal is to see if the drug leads to a 55% or greater reduction in disease severity scores.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIDRADENITIS SUPPURATIVA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could childhood trauma fuel skin inflammation?
- Head-to-Head: which pill tames hidradenitis suppurativa best?
- Skin disease evolution under the microscope: a 17-Year look at what drives severity
- Could early treatment tame a painful skin condition?
- New pill shows promise for controlling painful skin condition in long-term trial
- New shot could ease painful skin condition